uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

• Chardan’s 5^th Annual Genetic Medicines Conference, October 4 - 5, 2021
  
  
  
  
  • Members of uniQure’s management team, including , chief executive officer, will participate in virtual one-on-one investor meetings the morning of Tuesday, October 5^th.
    
    
    
    
  • A fireside chat with Matt Kapusta will take place the same day from 8:00 to 8:30 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the section of the uniQure website.
    
    
    
    
• Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa, October 12 - 14, 2021
  
  
  
  
  • Joshua Leeman, Ph.D., VP, Search & Evaluation, Business Development, will be making a corporate presentation on Wednesday, October 13^th at 12:15 p.m. PDT.
    
    
    
    
  • Dr. Leeman will also be participating in a panel entitled, “Delivering the Innovation of Gene Therapy to Patients Through Strategic Collaborations Workshop” on Thursday, October 14^th starting at 7:15 a.m. PDT.
    
    
    
    
• European Society of Gene and Cell Therapy (ESGCT), October 19 – 22. 2021
  
  
  
  
  • uniQure will present multiple preclinical data presentations at the meeting. Specific details to follow when the meeting abstracts are released.
    
    
    
    
• Jefferies Gene Therapy/Editing Summit, October 27 - 28, 2021
  
  
  
  
  • Members of uniQure’s management team including president of Research & Development, will participate virtually in one-on-one investor meetings throughout the day on Thursday, October 28^th.
    
    
    
    
  • A fireside chat with Matt Kapusta will take place the same day from 12:00 to 12:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the section of the uniQure website.
    
    

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.